ExonHit, BioMerieux Kill Colon Cancer Program, Continue to Develop Prostate Cancer Dxs
March 09, 2010
ExonHit, BioMerieux Kill Colon Cancer Program, Continue to Develop Prostate Cancer Dxs
The companies said that "final results from the colon cancer program did not reach the level of performance we were aiming to achieve." The firms, both based in France, are co-developing microarray-based tests that screen for a variety of cancer biomarkers in blood.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Philips, BioMerieux to Develop Biochips for Cardiovascular Diseases
January 26, 2010 / BioArray News - BioMerieux Takes $15M Stake in Quanterix, Gains Exclusive Global License to SiMoA as IVD Platform
November 30, 2012 / ProteoMonitor - BioMerieux Invests $15M in Quanterix, Will Use SiMoA to Support PSA and Infectious Disease Assays
November 27, 2012 / BioArray News - BioMerieux Invests $15M in Quanterix as Part of Test Development Partnership
November 15, 2012 / GenomeWeb Daily News - ASU's Biodesign Institute Wins $30M DoD Contract for Immunosignature-Based Pathogen Detection Chip
April 27, 2012 / ProteoMonitor